Jane Salodof MacNeil Dec. 9, 2002 (Philadelphia)—A multicenter European study has found that a new oral formulation of fludarabine phosphate (Fludara) is comparable to the intravenous (IV) version for patients with previously untreated B-cell chronic lymphocytic leukemia (CLL). Jean-Francois Ross...
Roche needs Tecentriq and other new launches such as AbbVie-partnered Venclexta (venetoclax) for chronic lymphocytic leukemia (CLL) to grow quickly as it starts to face the prospect of biosimilar competition for its big-selling antibody drugs. Overall, revenues at the Swiss pharma group rose 4...
In the EU, approval was granted for Alecensa as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC. In January 2018, EMA approved Ocrevus for the treatment of both the relapsing and the primary progressive forms of multiple...
Despite recent advances and successful combination therapies, a high unmet medical need remains for patients with relapsed/refractory AML. With the promising preliminary single-agent activity of flotetuzumab (CD123-CD3 = MGD006) in refractory AML,24 immunotherapy using TCE has gained much interest ...
The article discusses a study presented at the 57th Annual Meeting and Exposition of the American Society of Hematology in 2016 which shows that idelalisib in combination with rituximab (IR) when offered in patients with refractory chronic lymphocytic leukaemia (CLL) appears to be cost effective....
Good News from OSU About My CLL ( Chronic Lymphocytic Leukemia)
However the spontaneous apoptosis in B-CLLpatients was significantly lower compared to the healthy controlsthat confirmed the defective apoptosis as one of the mechanismsof leukemic lymphocytes accumulation in B-CLL. Continuing ourresearch, in the presented study we measured apoptosis of Band T cells ...
Single-Center Experience Indicates Relatively Good Prognosis After Allogeneic Stem Cell Transplantation Failure in CLLMatthew Stenger